메뉴 건너뛰기




Volumn 39, Issue 5, 2008, Pages 168-175

Treatment of osteoporosis in the elderly: What is the evidence?;Behandeling van osteoporose bij ouderen: Wat is de evidence?

Author keywords

Elderly; Fracture; Osteoporosis; Treatment

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; GLUCOCORTICOID; IBANDRONIC ACID; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; RALOXIFENE; RISEDRONIC ACID; STRONTIUM RANELATE; VITAMIN D; ZOLEDRONIC ACID;

EID: 54849433138     PISSN: 01679228     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03078150     Document Type: Review
Times cited : (2)

References (45)
  • 3
    • 0018222773 scopus 로고
    • Mean wall thickness in trabecular bone packets in the human iliac crest: Changes with age
    • Lips P, Courpron P, Meunier PJ. Mean wall thickness in trabecular bone packets in the human iliac crest: changes with age. Calcif Tissue Res 1978; 26: 13-7.
    • (1978) Calcif Tissue Res , vol.26 , pp. 13-17
    • Lips, P.1    Courpron, P.2    Meunier, P.J.3
  • 5
    • 34848817375 scopus 로고    scopus 로고
    • Quality indicators for the care of osteoporosis in vulnerable elders
    • Grossman J, Maclean CH. Quality indicators for the care of osteoporosis in vulnerable elders. J Am Geriatr Soc 2007; 55(suppl 2): S392-402.
    • (2007) J Am Geriatr Soc , vol.55 , Issue.SUPPL. 2
    • Grossman, J.1    Maclean, C.H.2
  • 6
    • 33646728619 scopus 로고    scopus 로고
    • Calcium and vitamin D in the prevention and treatment of osteoporosis - a clinical update
    • Jun;
    • Boonen S, Vanderschueren D, Haentjens P, Lips P. Calcium and vitamin D in the prevention and treatment of osteoporosis - a clinical update. J Intern Med 2006 Jun;259(6):s39-52.
    • (2006) J Intern Med , vol.259 , Issue.6
    • Boonen, S.1    Vanderschueren, D.2    Haentjens, P.3    Lips, P.4
  • 7
    • 34548047185 scopus 로고    scopus 로고
    • Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: A meta-analysis
    • Tang BMP, Eslick GD, Nowson C, et al. Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis. Lancet 2007; 370: 657-66.
    • (2007) Lancet , vol.370 , pp. 657-666
    • Tang, B.M.P.1    Eslick, G.D.2    Nowson, C.3
  • 8
    • 34147164190 scopus 로고    scopus 로고
    • Need for additional calcium to reduce the risk of hip fracture with vitamin D supplementation: Evidence from a comparative metaanalysis of randomized controlled trials
    • Boonen S, Lips P, Bouillon R, Bischoff-Ferrari HA, Vanderschueren D, Haentjens P. Need for additional calcium to reduce the risk of hip fracture with vitamin D supplementation: evidence from a comparative metaanalysis of randomized controlled trials. J Clin Endocrinol Metab 2007; 92(4): 1415-23.
    • (2007) J Clin Endocrinol Metab , vol.92 , Issue.4 , pp. 1415-1423
    • Boonen, S.1    Lips, P.2    Bouillon, R.3    Bischoff-Ferrari, H.A.4    Vanderschueren, D.5    Haentjens, P.6
  • 9
    • 39149101470 scopus 로고    scopus 로고
    • Vascular events in healthy older women receiving calcium supplementation: Randomised controlled trial
    • Bolland MJ, Barber PA, Doughty RN, et al. Vascular events in healthy older women receiving calcium supplementation: randomised controlled trial. BMJ 2008; 336: 262-266.
    • (2008) BMJ , vol.336 , pp. 262-266
    • Bolland, M.J.1    Barber, P.A.2    Doughty, R.N.3
  • 11
    • 18244397439 scopus 로고    scopus 로고
    • Fracture prevention with vitamin D supplementation: A meta-analysis of randomized controlled trials
    • Review
    • Bischoff-Ferrari HA, Willett WC, Wong JB, Giovanucci E, Dietrich T, Dawson-Hughes B. Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA 2005; 293(18): 2257-64. Review.
    • (2005) JAMA , vol.293 , Issue.18 , pp. 2257-2264
    • Bischoff-Ferrari, H.A.1    Willett, W.C.2    Wong, J.B.3    Giovanucci, E.4    Dietrich, T.5    Dawson-Hughes, B.6
  • 12
    • 0026613738 scopus 로고
    • Vitamin D3 and calcium to prevent hip fractures in the elderly women
    • Chapuy MC, Arlot ME, Duboeuf F, Brun J, Crouzet B, Arnaud S, et al. Vitamin D3 and calcium to prevent hip fractures in the elderly women. N Engl J Med 1992; 327(23): 1637-42.
    • (1992) N Engl J Med , vol.327 , Issue.23 , pp. 1637-1642
    • Chapuy, M.C.1    Arlot, M.E.2    Duboeuf, F.3    Brun, J.4    Crouzet, B.5    Arnaud, S.6
  • 13
    • 0030038417 scopus 로고    scopus 로고
    • Vitamin D supplementation and fracture incidence in elderly persons. A randomized, placebo-controlled clinical trial
    • Lips P, Graafmans WC, Ooms ME, Bezemer PD, Bouter LM. Vitamin D supplementation and fracture incidence in elderly persons. A randomized, placebo-controlled clinical trial. Ann Intern Med 1996; 124(4): 400-6.
    • (1996) Ann Intern Med , vol.124 , Issue.4 , pp. 400-406
    • Lips, P.1    Graafmans, W.C.2    Ooms, M.E.3    Bezemer, P.D.4    Bouter, L.M.5
  • 14
    • 32444444758 scopus 로고    scopus 로고
    • The application of evidence-based principles of care in older persons (issue 1): Management of osteoporosis
    • Zarowitz BJ, Stefanicci R, Hollenack K, et al. The application of evidence-based principles of care in older persons (issue 1): management of osteoporosis. J Am Med Dir Assoc 2006; 7: 102-8.
    • (2006) J Am Med Dir Assoc , vol.7 , pp. 102-108
    • Zarowitz, B.J.1    Stefanicci, R.2    Hollenack, K.3
  • 15
    • 34447250091 scopus 로고    scopus 로고
    • Pharmacological treatment of osteoporosis for people over 70
    • Alvarez MJM, Diaz-Curiel M. Pharmacological treatment of osteoporosis for people over 70. Aging Clin Exp Res 2007; 19: 246-54.
    • (2007) Aging Clin Exp Res , vol.19 , pp. 246-254
    • Alvarez, M.J.M.1    Diaz-Curiel, M.2
  • 16
    • 0004851872 scopus 로고    scopus 로고
    • Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral
    • Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral. Lancet 1996; 348: 1535-41.
    • (1996) Lancet , vol.348 , pp. 1535-1541
    • Black, D.M.1    Cummings, S.R.2    Karpf, D.B.3
  • 17
    • 0032583492 scopus 로고    scopus 로고
    • Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial
    • Cummings SR, Black DM, Thompson DE. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998; 280: 2077-82.
    • (1998) JAMA , vol.280 , pp. 2077-2082
    • Cummings, S.R.1    Black, D.M.2    Thompson, D.E.3
  • 18
    • 0033552255 scopus 로고    scopus 로고
    • Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group
    • Oct 13;
    • Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999 Oct 13;282(14):1344-52.
    • (1999) JAMA , vol.282 , Issue.14 , pp. 1344-1352
    • Harris, S.T.1    Watts, N.B.2    Genant, H.K.3    McKeever, C.D.4    Hangartner, T.5    Keller, M.6
  • 19
    • 0035253489 scopus 로고    scopus 로고
    • Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group
    • McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001; 344: 333-40.
    • (2001) N Engl J Med , vol.344 , pp. 333-340
    • McClung, M.R.1    Geusens, P.2    Miller, P.D.3
  • 20
    • 0036678372 scopus 로고    scopus 로고
    • IX: Summery of meta-analyses of therapies for postmenopausal osteoporosis
    • Cranney A, Guyatt G, Griffith L, et al. IX: Summery of meta-analyses of therapies for postmenopausal osteoporosis. Endocrine Reviews 2002; 23: 570-578.
    • (2002) Endocrine Reviews , vol.23 , pp. 570-578
    • Cranney, A.1    Guyatt, G.2    Griffith, L.3
  • 21
    • 25844504632 scopus 로고    scopus 로고
    • Effect of osteoporosis treatments on risk of non-vertebral fractures: Review and meta-analysis of intention-to-treat studies
    • Boonen S, Laan RF, Barton IP, Watts NB. Effect of osteoporosis treatments on risk of non-vertebral fractures: review and meta-analysis of intention-to-treat studies. Osteoporos Int 2005; 16(10): 1291-8.
    • (2005) Osteoporos Int , vol.16 , Issue.10 , pp. 1291-1298
    • Boonen, S.1    Laan, R.F.2    Barton, I.P.3    Watts, N.B.4
  • 22
    • 54849415164 scopus 로고    scopus 로고
    • Hochberg MC, Thompson DE, Black D. The effect of alendronate on age-specific incidence of key osteoporotic fractures. Bone 2001; 28 (suppl 5): P576S. (Joint meeting of the International Bone and Mineral Society and the European Calcified Tissue Society, June 2001, Madrid, Spain.)
    • Hochberg MC, Thompson DE, Black D. The effect of alendronate on age-specific incidence of key osteoporotic fractures. Bone 2001; 28 (suppl 5): P576S. (Joint meeting of the International Bone and Mineral Society and the European Calcified Tissue Society, June 2001, Madrid, Spain.)
  • 23
    • 4644346180 scopus 로고    scopus 로고
    • Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: Implications for use of antiresorptive agents in the old and oldest old
    • Boonen S, McClung MR, Eastel R, et al. Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: Implications for use of antiresorptive agents in the old and oldest old. J Am Geriatr Soc 2004; 52: 1832-9.
    • (2004) J Am Geriatr Soc , vol.52 , pp. 1832-1839
    • Boonen, S.1    McClung, M.R.2    Eastel, R.3
  • 24
    • 23744507892 scopus 로고    scopus 로고
    • The prevention of hip fracture with risedronate and ergocalciferol plus calcium supplementation in elderly women with Alzheimer disease: A randomized controlled trial
    • Sato Y, Kanoko K, Satoh K, Iwamoto J. The prevention of hip fracture with risedronate and ergocalciferol plus calcium supplementation in elderly women with Alzheimer disease: a randomized controlled trial. Arch Intern Med 2005; 165: 1737-42.
    • (2005) Arch Intern Med , vol.165 , pp. 1737-1742
    • Sato, Y.1    Kanoko, K.2    Satoh, K.3    Iwamoto, J.4
  • 25
    • 14644438517 scopus 로고    scopus 로고
    • Risedronate sodium therapy for prevention of hip fracture after stroke in elderly women
    • Sato Y, Kanoko K, Satoh K, Iwamoto J. Risedronate sodium therapy for prevention of hip fracture after stroke in elderly women. Neurol 2005; 64: 811-816.
    • (2005) Neurol , vol.64 , pp. 811-816
    • Sato, Y.1    Kanoko, K.2    Satoh, K.3    Iwamoto, J.4
  • 26
    • 23744484933 scopus 로고    scopus 로고
    • Risedronate sodium therapy for prevention of hip fracture in men 65 years or older after stroke
    • Sato Y, Kanoko K, Satoh K, Iwamoto J. Risedronate sodium therapy for prevention of hip fracture in men 65 years or older after stroke. Arch Intern Med 2005; 165: 1743-8.
    • (2005) Arch Intern Med , vol.165 , pp. 1743-1748
    • Sato, Y.1    Kanoko, K.2    Satoh, K.3    Iwamoto, J.4
  • 27
    • 34147108671 scopus 로고    scopus 로고
    • Risedronate and ergocalciferol prevent hip fracture in elderly men with Parkinson disease
    • Sato Y, Honda Y, Iwamoto J. Risedronate and ergocalciferol prevent hip fracture in elderly men with Parkinson disease. Neurol 2007; 68: 911-915.
    • (2007) Neurol , vol.68 , pp. 911-915
    • Sato, Y.1    Honda, Y.2    Iwamoto, J.3
  • 28
    • 35548986745 scopus 로고    scopus 로고
    • The cost effectiveness of bisphosphonates for the prevention and treatment of osteoporosis. A structured review of the literature
    • Fleurence RL, Iglesias CP, Johnson JM. The cost effectiveness of bisphosphonates for the prevention and treatment of osteoporosis. A structured review of the literature. Pharmacoeconomics 2007; 25: 913-33.
    • (2007) Pharmacoeconomics , vol.25 , pp. 913-933
    • Fleurence, R.L.1    Iglesias, C.P.2    Johnson, J.M.3
  • 29
    • 34547755634 scopus 로고    scopus 로고
    • Cost-effectiveness of bone densitometry followed by treatment of osteoporosis in older men
    • Schousboe JT, Taylor BC, Fink HA, et al. Cost-effectiveness of bone densitometry followed by treatment of osteoporosis in older men. JAMA 2007; 298: 629-37.
    • (2007) JAMA , vol.298 , pp. 629-637
    • Schousboe, J.T.1    Taylor, B.C.2    Fink, H.A.3
  • 30
    • 4544262219 scopus 로고    scopus 로고
    • Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis
    • Chesnut III CH, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004; 19: 1241-9.
    • (2004) J Bone Miner Res , vol.19 , pp. 1241-1249
    • Chesnut III, C.H.1    Skag, A.2    Christiansen, C.3
  • 31
    • 0141650559 scopus 로고    scopus 로고
    • Intravenous ibandronate injections given every three months: A new treatment option to prevent bone loss in postmenopausal women. Ibandronate Intravenous Study Group
    • Stakkestad JA, Benevolenskaya LI, Stepan JJ, Skag A, Nordby A, Oefjord E, et al. Intravenous ibandronate injections given every three months: a new treatment option to prevent bone loss in postmenopausal women. Ibandronate Intravenous Study Group. Ann Rheum Dis 2003; 62: 969-75.
    • (2003) Ann Rheum Dis , vol.62 , pp. 969-975
    • Stakkestad, J.A.1    Benevolenskaya, L.I.2    Stepan, J.J.3    Skag, A.4    Nordby, A.5    Oefjord, E.6
  • 32
    • 20144389195 scopus 로고    scopus 로고
    • Ibandronate produces significant, similar antifracture efficacy in North American and European women: New clinical findings from BONE
    • Chesnut CH, Ettinger MP, Miller PD, Baylink DJ, Emkey R, Harris ST, et al. Ibandronate produces significant, similar antifracture efficacy in North American and European women: new clinical findings from BONE. Curr Med Res Opin 2005; 21: 391-401.
    • (2005) Curr Med Res Opin , vol.21 , pp. 391-401
    • Chesnut, C.H.1    Ettinger, M.P.2    Miller, P.D.3    Baylink, D.J.4    Emkey, R.5    Harris, S.T.6
  • 33
    • 4344580653 scopus 로고    scopus 로고
    • Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: Results from the BONE study
    • Delmas PD, Recker RR, Chesnut 3rd CH, Skag A, Stakkestad JA, Emkey R, et al. Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporos Int 2004;15:792-8.
    • (2004) Osteoporos Int , vol.15 , pp. 792-798
    • Delmas, P.D.1    Recker, R.R.2    Chesnut 3rd, C.H.3    Skag, A.4    Stakkestad, J.A.5    Emkey, R.6
  • 34
    • 34247844628 scopus 로고    scopus 로고
    • Treatments for osteoporosis - looking beyond the HORIZON
    • Compston J. Treatments for osteoporosis - looking beyond the HORIZON. N Engl J Med 2007;356:1878-80.
    • (2007) N Engl J Med , vol.356 , pp. 1878-1880
    • Compston, J.1
  • 35
    • 34247866550 scopus 로고    scopus 로고
    • Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. HORIZON Pivotal Fracture Trial
    • Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. HORIZON Pivotal Fracture Trial. N Engl J Med 2007; 356: 1809-22.
    • (2007) N Engl J Med , vol.356 , pp. 1809-1822
    • Black, D.M.1    Delmas, P.D.2    Eastell, R.3    Reid, I.R.4    Boonen, S.5    Cauley, J.A.6
  • 36
    • 35748967004 scopus 로고    scopus 로고
    • Zoledronic acid and clinical fractures and mortality after hip fracture
    • Lyles KW, Colón-Emeric CS, Jay S, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007; 357(18): 1799-809.
    • (2007) N Engl J Med , vol.357 , Issue.18 , pp. 1799-1809
    • Lyles, K.W.1    Colón-Emeric, C.S.2    Jay, S.3
  • 37
    • 9144233479 scopus 로고    scopus 로고
    • The effects of strontium ranelate on the risk of vertebral fractures in women with post-menopausal osteoporosis
    • Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fractures in women with post-menopausal osteoporosis. N Engl J Med 2004; 350: 459-68.
    • (2004) N Engl J Med , vol.350 , pp. 459-468
    • Meunier, P.J.1    Roux, C.2    Seeman, E.3
  • 38
    • 21044447888 scopus 로고    scopus 로고
    • Reginster JY, Seeman E, Vernejoul MC de, et al. Strontium ranelate reduces the risk of non-vertebral fractures in post-menopausal women with osteoporosis: Treatment of Periferal Osteoporosis (TROPOS) study. J Clin End Metab 2005; 90: 2816-22.
    • Reginster JY, Seeman E, Vernejoul MC de, et al. Strontium ranelate reduces the risk of non-vertebral fractures in post-menopausal women with osteoporosis: Treatment of Periferal Osteoporosis (TROPOS) study. J Clin End Metab 2005; 90: 2816-22.
  • 40
    • 0035837553 scopus 로고    scopus 로고
    • Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis
    • Neer RM, Arnoud CD, Zanchetti JR, Prince R, Gaich GA, Reginster JY, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344: 1434-41.
    • (2001) N Engl J Med , vol.344 , pp. 1434-1441
    • Neer, R.M.1    Arnoud, C.D.2    Zanchetti, J.R.3    Prince, R.4    Gaich, G.A.5    Reginster, J.Y.6
  • 41
    • 33947504500 scopus 로고    scopus 로고
    • Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis
    • Greenspan SL, Bone HG, Ettinger MP, et al. Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis. Ann Intern Med 2007; 146: 326-339.
    • (2007) Ann Intern Med , vol.146 , pp. 326-339
    • Greenspan, S.L.1    Bone, H.G.2    Ettinger, M.P.3
  • 42
    • 0037216436 scopus 로고    scopus 로고
    • The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis
    • Marcus R, Wang O, Satterwhite J, et al. The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis. J Bone Miner Res 2003; 18: 18-23.
    • (2003) J Bone Miner Res , vol.18 , pp. 18-23
    • Marcus, R.1    Wang, O.2    Satterwhite, J.3
  • 43
    • 33744973067 scopus 로고    scopus 로고
    • Safety and efficacy of teriparatide in elderly women with established osteoporosis: Bone anabolic therapy from a geriatric perspective
    • Boonen S, Marin F, Mellstrom D, Xie L, Desaiah D, Krege JH, Rosen CJ. Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective. J Am Geriatr Soc 2006; 54(5): 782-9.
    • (2006) J Am Geriatr Soc , vol.54 , Issue.5 , pp. 782-789
    • Boonen, S.1    Marin, F.2    Mellstrom, D.3    Xie, L.4    Desaiah, D.5    Krege, J.H.6    Rosen, C.J.7
  • 44
    • 0033581212 scopus 로고    scopus 로고
    • Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators
    • Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999; 282: 637-45.
    • (1999) JAMA , vol.282 , pp. 637-645
    • Ettinger, B.1    Black, D.M.2    Mitlak, B.H.3
  • 45
    • 31144466851 scopus 로고    scopus 로고
    • Osteoporosis in postmenopausal women. Therapy options across a wide range of risk for fracture
    • Miller RG. Osteoporosis in postmenopausal women. Therapy options across a wide range of risk for fracture. Geriatrics 2006; 61: 24-30.
    • (2006) Geriatrics , vol.61 , pp. 24-30
    • Miller, R.G.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.